Lv71
4880 积分 2021-12-22 加入
Innovative Pharmacological Approaches to Hypertrophic Cardiomyopathy: The Emerging Role of Aficamten
1个月前
已完结
Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3
1个月前
已完结
Aficamten and Cardiopulmonary Exercise Test Performance
1个月前
已完结
Aficamten in Hypertrophic Cardiomyopathy
1个月前
已完结
Aficamten reduces symptoms in obstructive hypertrophic cardiomyopathy
1个月前
已完结
Aficamten for Obstructive Hypertrophic Cardiomyopathy
1个月前
已完结
Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy
1个月前
已完结
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4
1个月前
已完结
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy
1个月前
已完结
Safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy: A 36‐week analysis from FOREST‐HCM
1个月前
已完结
皖公网安备34019202002308
